<DOC>
	<DOCNO>NCT01230983</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . Dexrazoxane may lessen side effect chemotherapy . PURPOSE : Randomized phase III trial compare combination chemotherapy without dexrazoxane without high-dose methotrexate patient acute lymphoblastic leukemia advance lymphoblastic non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Acute Lymphoblastic Leukemia Advanced Lymphoblastic Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine , randomize trial , effectiveness high-dose methotrexate add multiagent chemotherapy backbone ( Dana Farber Cancer Institute regimen , protocol DFCI-87001 ) proven effective T-cell acute lymphoblastic leukemia ( T-ALL ) advance lymphoblastic non-Hodgkin 's lymphoma ( NHL ) . II . Determine role dexrazoxane prevent cardiotoxicity child T-ALL advance lymphoblastic NHL treat anthracycline-based regimen . III . Study biology T-cell lymphoid malignancy accumulate data concurrent ALL classification study ( POG-9400 ) analyze data relative outcome . IV . Evaluate correlation minimal residual disease ( use TAL 1 proto-oncogene ) event-free survival . V. Determine role p53 p16 tumor suppressor gene T-ALL . VI . Determine whether drug sensitivity profile blast cell doxorubicin , methotrexate , cytarabine correlate initial response subsequent relapse . OUTLINE : This randomize , multicenter study . Patients stratify accord disease category ( acute lymphoblastic leukemia ( ALL ) CNS disease vs. ALL CNS disease vs. non-Hodgkin 's lymphoma ( NHL ) CNS disease vs. NHL CNS disease ) , gender , race ( Caucasian vs. African American vs. Hispanic ) . Patients randomize one four treatment arm . ARM I : During induction therapy , patient receive vincristine IV daily day 1 , 8 , 15 , 22 , oral prednisone three time day day 1-21 , doxorubicin IV daily day 1 , 2 , 22 , methotrexate IV , least 8 hour doxorubicin day 2 , oral mercaptopurine daily day 22-35 . Patients receive triple intrathecal therapy ( TIT ) consist methotrexate , cytarabine , hydrocortisone week 1 , 3 , 4 , 5 , 6 . Patients CNS 2 3 disease receive TIT week 2 . During week 7-33 , patient receive consolidation therapy consist vincristine IV every 3 week , oral prednisone three time day 5 day , every 3 week , doxorubicin IV every 3 week , oral mercaptopurine daily 14 day , every 3 week , asparaginase intramuscularly ( IM ) weekly week 7-26 . Patients receive TIT week 10 22 ( week 16 patient CNS 2 3 disease ) . Patients receive radiotherapy begin week 22 . During week 34-108 , patient receive continuation therapy consist vincristine IV every 3 week , oral prednisone three time day 5 day , every 3 week , methotrexate IV IM weekly ( omit TIT ) oral mercaptopurine daily 14 day , every 3 week . Patients receive TIT week 40 , 58 , 76 , 94 . Arm II : Patients receive induction therapy Arm I addition dexrazoxane IV give prior doxorubicin day 1 , 2 , 22 . Patients receive consolidation therapy Arm I addition dexrazoxane IV give prior doxorubicin every 3 week . Patients receive continuation therapy Arm I . Arm III : Patients receive induction therapy Arm I addition high dose methotrexate IV week 4 leucovorin calcium IV orally every 6 hour 7 dos begin 36 hour high dose methotrexate . Patients receive consolidation therapy Arm I addition high dose methotrexate IV week 7 , 10 , 13 follow leucovorin calcium induction therapy . Patients receive continuation therapy Arm I . Arm IV : Patients receive induction therapy consolidation therapy Arms I , II , III . Patients receive continuation therapy Arm I . Treatment continue 108 week absence disease progression unacceptable toxicity . Patients follow every 2 month 1 year , every 4 month 3 year , every 6 month 2 year . PROJECTED ACCRUAL : A total 494 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Cardiotoxicity</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Dexrazoxane</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Razoxane</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Tcell acute lymphoblastic leukemia ( ALL ) Registration current ALL classification study ( POG9400 ) require within 6 working day prior entry DR , T+ DR , T DR+ , T+ eligible Tcell ALL confirm Johns Hopkins Reference Laboratory Biopsyproven diffuse lymphoblastic lymphoma Murphy stage III/IV disease Registered ALL classification study ( POG9400 ) PATIENT CHARACTERISTICS : Age : Over 12 month 22 year TALL Under 22 year lymphoma PRIOR CONCURRENT THERAPY : No prior therapy steroid emergency mediastinal irradiation patient severe respiratory distress mediastinal disease Steroid treatment allow provided physical examination complete blood count differential perform immediately prior begin steroids result know</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>stage III childhood lymphoblastic lymphoma</keyword>
	<keyword>stage IV childhood lymphoblastic lymphoma</keyword>
	<keyword>untreated childhood acute lymphoblastic leukemia</keyword>
	<keyword>T-cell childhood acute lymphoblastic leukemia</keyword>
	<keyword>cardiac toxicity</keyword>
</DOC>